Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice

Authors: Saqi, Anjali, Leslie, Kevin O., Moreira, Andre L., Lantuejoul, Sylvie, Shu, Catherine Ann, Rizvi, Naiyer A., Sonett, Joshua R., Tajima, Kosei, Sun, Shawn W., Gitlitz, Barbara J., Colby, Thomas V.

Source: In JTO Clinical and Research Reports May 2022 3(5)

Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC

Authors: Lee, Jay M., Kim, Anthony W., Marjanski, Tomasz, Falcoz, Pierre-Emmanuel, Tsuboi, Masahiro, Wu, Yi-Long, Sun, Shawn W., Gitlitz, Barbara J.

Source: In JTO Clinical and Research Reports October 2021 2(10)

OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer.

Authors: Tolaney, Sara M, DeMichele, Angela, Takano, Toshimi, Rugo, Hope S, Perou, Charles, Lynce, Filipa, Parsons, Heather Anne, Santa-Maria, Cesar Augusto, Rocque, Gabrielle Betty, Yao, Wenliang, Sun, Shawn W, Mocci, Simonetta, Partridge, Ann H, Carey, Lisa A

Source: Future Oncology; 2024, Vol. 20 Issue 31, p2343-2355, 13p

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Authors: Jotte, Robert, Cappuzzo, Federico, Vynnychenko, Ihor, Stroyakovskiy, Daniil, Rodríguez-Abreu, Delvys, Hussein, Maen, Soo, Ross, Conter, Henry J., Kozuki, Toshiyuki, Huang, Kuan-Chieh, Graupner, Vilma, Sun, Shawn W., Hoang, Tien, Jessop, Helen, McCleland, Mark, Ballinger, Marcus, Sandler, Alan, Socinski, Mark A.

Source: In Journal of Thoracic Oncology August 2020 15(8):1351-1360

Activation of Neuronal Gene Expression by the JMJD3 Demethylase Is Required for Postnatal and Adult Brain Neurogenesis

Authors: Park, Dae Hwi, Hong, Sung Jun, Salinas, Ryan D., Liu, Siyuan John, Sun, Shawn W., Sgualdino, Jacopo, Testa, Giuseppe, Matzuk, Martin M., Iwamori, Naoki, Lim, Daniel A.

Source: In Cell Reports 11 September 2014 8(5):1290-1299

ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual...

Authors: Tolaney, Sara M., DeMichele, Angela, Takano, Toshimi, Rugo, Hope S., Perou, Charles, Metzger, Otto, Parsons, Heather Anne, Santa-Maria, Cesar Augusto, Rocque, Gabrielle Betty, Yao, Wenliang, Sun, Shawn W., Mocci, Simonetta, Partridge, Ann H., Carey, Lisa A.

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS619-TPS619, 1p

Important Surgical and Clinical Endpoints in Neoadjuvant Immunotherapy Trials in Resectable Non-Small Cell Lung Cancer

Authors: Lee, Jay M., Kim, Anthony W., Marjanski, Tomasz, Falcoz, Pierre-Emmanuel, Tsuboi, Masahiro, Wu, Yi-Long, Sun, Shawn W., Gitlitz, Barbara J.

Source: JTO Clinical and Research Reports; 20210101, Issue: Preprints